Two public life‑science tool and diagnostics firms posted preliminary quarterlies with testing and consumables at the center. 10x Genomics reported expected Q4 revenue of $166 million—above estimates—driven by consumables growth while instrument sales declined; the company flagged full‑year consumables strength but ongoing instrument pressures. Veracyte said preliminary Q4 revenue of $138–$140 million, driven by testing volume, and guided 2026 revenue up 10–13% as testing-led growth continues. Both companies emphasized recurring consumables and test volumes as durable revenue engines, even as capital equipment cycles stay uneven. Market reaction will hinge on whether consumables growth offsets instrument headwinds and supports margin expansion across 2026.